AstraZeneca CEO Pascal Soriot Receives Significant Pay Rise Amid Controversy

Pascal Soriot, the chief executive of AstraZeneca, received a 6.4% pay rise in 2025, bringing his total remuneration to £17.7 million. This increase follows a year in which AstraZeneca, the largest pharmaceutical company in Britain, experienced a 32% rise in share price and an 8% increase in revenues, totaling $58.7 billion, primarily driven by strong sales of cancer treatments. Soriot's compensation includes a salary of £1.5 million, annual bonuses of £4.3 million, and long-term share bonuses worth £11.6 million. For 2026, he is projected to earn up to £19.6 million, which could make him the highest-paid chief executive in the UK once again.

The Guardian

Despite Soriot's substantial pay increase, AstraZeneca has faced significant operational challenges. The company recently canceled a planned £450 million expansion of its vaccine site in Speke, near Liverpool, and halted a £200 million investment in research in Cambridge due to disputes with the UK government over drug pricing and the availability of new medicines on the National Health Service (NHS). Notably, AstraZeneca's breast cancer infusion, Enhertu, is currently only available through private channels.

The Guardian

Soriot's pay has sparked controversy, particularly as it comes amid ongoing discussions about fair compensation in the corporate sector. The High Pay Centre, an organization advocating for equitable pay, reported that executives at Britain's largest listed companies received record-high pay packets for the third consecutive year. This trend has led to shareholder rebellions against excessive executive compensation, despite AstraZeneca's improved financial performance.

The Guardian

AstraZeneca's annual report highlights the company's strong financial results, which have contributed to Soriot's pay increase. However, the company's decision to cancel significant investments has raised questions about its commitment to long-term growth and innovation. Critics argue that high executive pay, particularly in the context of halted investments, reflects a misalignment of priorities within the company.

The Guardian

• “The High Pay Centre, which campaigns for fairer pay, found in August that the bosses of Britain’s largest listed companies took home record-high pay packets for the third year in a row.” — High Pay Centre

The Guardian

As AstraZeneca continues to navigate its operational challenges and shareholder concerns, the company is expected to focus on expanding its pipeline of blockbuster medicines, with a goal of increasing from 16 to 25 by 2030. The ongoing discussions regarding drug pricing and NHS access will likely influence future investment decisions and executive compensation strategies.

The Guardian